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Abstract Tissue microarray (TMA) technology has been
developed to facilitate high-throughput immunohistochem-
ical and in situ hybridization analysis of tissues by inserting
small tissue biopsy cores into a single paraffin block.
Several studies have revealed novel prognostic biomarkers
in esophageal squamous cell carcinoma (ESCC) by means
of TMA technology, although this technique has not yet
been validated for these tumors. Because representativeness
of the donor tissue cores may be a disadvantage compared
to full sections, the aim of this study was to assess if TMA
technology provides representative immunohistochemical
results in ESCC. A TMA was constructed containing
triplicate cores of 108 formalin-fixed, paraffin-embedded
squamous cell carcinomas of the esophagus. The agreement
in the differentiation grade and immunohistochemical
staining scores of CK5/6, CK14, E-cadherin, Ki-67, and
p53 between TMA cores and a subset of 64 randomly
selected donor paraffin blocks was determined using kappa
statistics. The concurrence between TMA cores and donor
blocks was moderate for Ki-67 (κ=0.42) and E-cadherin
(κ=0.47), substantial for differentiation grade (κ=0.65) and
CK14 (κ=0.71), and almost perfect for p53 (κ=0.86) and
CK5/6 (κ=0.93). TMA technology appears to be a valid
method for immunohistochemical analysis of molecular
markers in ESCC provided that the staining pattern in the
tumor is homogeneous.
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Introduction
Esophageal carcinoma is the eighth most common type of
cancer in the world [13]. Although the recent rise in
incidence of esophageal cancer has predominantly been
caused by an increase in adenocarcinomas, the majority of
esophageal cancer cases globally are squamous cell
carcinomas [13]. For both histological types, radical en
bloc esophagectomy with an extensive lymph node dissec-
tion offers the best chance for cure, leading to an overall
5-year survival rate of around 30% [1, 20].
Well-known histopathological factors for prognostication
of esophageal cancer include the TNM stage, the number of
positive lymph nodes, and the presence of extracapsular
lymph node involvement [16, 24, 26, 32]. Recently, there
has been a growing interest in the prognostic value of
molecular markers in (esophageal) cancer [21]. The
expression of such markers is often studied by immunohis-
tochemistry on formalin-fixed, paraffin-embedded tumor
slides. Tissue microarray (TMA) technology has been
developed to enable high-throughput immunohistochemical
analyses [14]. By inserting small (diameter e.g. 0.6 mm)
donor tissue core biopsies into a single recipient paraffin
block, this technique allows for rapid analysis of large
numbers of tissues under standardized laboratory and evalu-
ation conditions without significantly damaging the patient’s
tissue. In addition, TMA technology leads to a significant
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A potential disadvantage compared to full tissue sections
is that the donor cores may not be representative for the
whole tumor, particularly in case of heterogeneous tumors
and heterogeneously expressed molecular markers. Hence,
some validation studies have been performed in various
cancers using different kinds of antibodies [2, 4, 6, 7, 9, 12,
23, 35]. Although several studies have revealed novel
prognostic biomarkers in esophageal squamous cell cancer
(ESCC) by means of TMA technology [38, 39, 41], this
technique has not yet been validated for these tumors.
The aim of the present study was, therefore, to validate
TMA technology in ESCC by assessing the concurrence of
immunohistochemical staining scores of established molec-
ular markers with various expression patterns between
triplicate 0.6 mm core biopsies of the TMA and their
whole tissue section counterparts.
Materials and methods
TMA construction
Formalin-fixed, paraffin-embedded tissues from thoracic
ESCCs of consecutive patients having undergone esoph-
agolymphadenectomy at the authors’ institute between
1989 and 2006 were retrieved from the archives of the
Department of Pathology. Patients who received neoadju-
vant therapy were excluded from this study. The study was
carried out in accordance with the ethical guidelines of our
institution concerning informed consent about the use of
patient’s materials after surgical procedures.
By an experienced pathologist (FtK), three representa-
tive tumor regions were marked on one selected hematox-
ylin and eosin (H&E)-stained section of each tumor,
avoiding areas of necrosis. From these three tumor regions,
a tissue cylinder with a diameter of 0.6 mm was punched
out of the corresponding paraffin block (‘donor block’) and
placed into the TMA paraffin block using a manual tissue
arrayer (MTA-I, Beecher Instruments, Sun Prairie, USA),
which was guided by the MTABooster® (Alphelys, Plaisir,
France). The distribution and position of the cores was
determined in advance with the TMA-designer Software
(Alphelys-TMA Designer®, Version 1.6.8, Plaisir, France).
Cores of normal esophageal mucosa, lymph node, kidney,
liver, spleen, and prostate were incorporated in the tissue
array block as internal controls.
Immunohistochemistry
For each marker, a 4-μm slide of the TMA and one of every
selected donor paraffin block were immunohistochemically
stained. Table 1 shows the details of all antibodies,
dilutions, incubation times and antigen retrieval methods
applied in this study.
For all stainings, sections were deparaffinized in xylene
for 10 min followed by dehydration through graded
alcohols. Endogenous peroxidase activity was blocked for
15 min in a buffer solution of pH 5.8 (containing 8.32 g
citric acid, 21.52 g disodium hydrogen phosphate, 2 g
sodium azide in 1 l of water) with hydrogen peroxide
(0.3%). After antigen retrieval for 20 min, a cooling down
period of 30 min was followed by incubation with the
primary antibody. Depending on the antibody used, slides
were incubated with the secondary antibody followed by
Table 1 Specification of antibodies used and details of tissue processing
Primary
antibody
Staining
pattern
Source
a Clone and
code
Antigen
retrieval
Dilution Incubation
time (min/room
temperature)
Detection
b Positive control Procedure
CK5/6 Cytoplasmic Chemicon D5/16 B4 EDTA pH 9.0 1:3,000 60 Strept ABC Breast Autostainer
CK14 Cytoplasmic Neomarkers LL002 EDTA pH 9.0 1:400 60 Powervision Breast Autostainer
E-cadherin Membranous Zymed 4A2C7 Citrate autoclave
pH 6.0
1:200 60 Powervision Breast Autostainer
MIB-1
(Ki-67)
Nuclear Dako M7240 Citrate pH 6.0 1:100 60 Strept ABC Tonsil Autostainer
p53 Nuclear Biogenex BP53-12 Citrate pH 6.0 1:200 60 Strept ABC Serous
adenocarcinoma
of the
endometrium
Autostainer
aBiogenex, San Ramon, CA, USA; Chemicon, Chemicon International, Temecula, CA, USA; Dako, DakoCytomation, Glostrup, Denmark;
Neomarkers, Fremont, USA; Zymed, Zymed Laboratories, San Francisco, CA, USA.
bStrept ABC is biotinylated horse–antimouse Vector BA-2000, diluted 1:500 in PBS, followed by streptavidin–biotin complex, diluted 1:1,000.
Powervision ready to use (Poly-HRP-antiMs/Rb/RtIgG biotin-free; ImmunoVision Technologies, Norwell, CA, USA).
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incubated with Powervision (details of both products shown
in the legend of Table 1). Then, the peroxidase reactivity
was developed by 3,3′-diaminobenzidine for 10 min and
slides were counterstained with Mayer’s hematoxylin. In
between steps, slides were washed with phosphate-buffered
saline (pH 7.4).
Immunohistochemical scoring
By two observers (FtK and JB) conjointly, the degree of
differentiation and the percentage of immunohistochemi-
cally stained tumor cells were determined in all TMA cores
and in the full sections of the selected donor blocks.
Histologic grade was scored as well-differentiated (G1),
moderately differentiated (G2), or poorly differentiated
(G3) [37]. Staining of p53 and Ki-67 were marked as
negative (<10% of tumor nuclei stained), weakly positive
(10–50%), or strongly positive (≥50%) [10, 40]. Cytoker-
atin (CK)5/6 and CK14 staining were scored as negative
(<10% of tumor cell cytoplasms stained), weakly positive
(10–80%), or strongly positive (≥80%). E-cadherin
expression was regarded negative when <50% of tumor
cell membranes stained and positive when ≥50% stained
[29, 30].
Cores were considered lost if <10% of cells contained
tumor (‘sampling error’) or when <10% of tissue was
present (‘absent core’). Cases were excluded if two out of
three cores were lost. When the scores between the cores of
a particular case differed, the most frequent score deter-
mined the overall score. In case of three different scores in
one case, the middle score was chosen. When only two
cores were available with both a different score, the case
was excluded from further analysis [11].
Statistical analysis
Statistical analyses were performed using the SPSS soft-
ware for Windows (Version 12.0, SPSS, Chicago, IL,
USA). Sixty-four donor blocks (60% of the tumors
incorporated in the TMA) were randomly chosen by means
of a random selection function of SPSS.
To determine the chance-corrected agreement between
the immunohistochemical staining scores of TMA cores
and large sections, the Cohen’s weighted kappa statistic was
calculated. Chance-corrected agreement was considered
poor if κ<0.00, slight if 0<κ<0.20, fair if 0.21<κ<0.40,
moderate if 0.41<κ<0.60, substantial if 0.61<κ<0.80, and
almost perfect if 0.81<κ<1.00 [17]. The overall agreement
was defined as the percentage of correct agreement between
the TMA and the donor blocks from the total number of
cases [15].
Results
Of the 324 (3×108) tumor tissue cores that were transferred
into the TMA paraffin block, a median of 295 (91%) was
available for immunohistochemical scoring on the 6 TMA
slides used in this study (Table 2). Of the 64 randomly
selected cases, a median of 176 (92%) of 192 cores (3×64)
was evaluable on the TMA slides.
On the H&E-stained TMA slide, 49 (76%) of the 64
randomly chosen cases were represented by 3 cores; 14
(22%) by 2 cores. One (1.6%) case was excluded from
further analysis because only a single core was available.
The agreement in the scores for the grade of differentiation
between the TMA cores and the full sections is shown in
Table 3. The weighted kappa score was 0.65.
Table 2 Overview of the amount of cores that were evaluable, absent or contained too little tumor in all 108 cases and in the 64 randomly
selected cases on the TMA slides
H&E CK5/6 CK14 E-cadherin Ki-67 p53 Median
Total TMA cases (n=108)
No. of evaluable cores 293 309 294 306 293 295 295
Percentage 90 95 91 94 90 91 91
No. of absent cores 20 7 22 9 22 22 21
Percentage 6 2 7 3 7 7 6
No. of cores without tumor 11 8 8 9 9 7 9
Percentage 4 3 3 3 3 2 3
Randomly selected TMA cases (n=64)
No. of evaluable cores 176 187 176 185 176 176 176
Percentage 92 97 92 96 92 92 92
No. of absent cores 13 3 13 4 13 13 13
Percentage 7 2 7 2 7 7 7
No. of cores without tumor 3 2 3 3 3 3 3
Percentage 2 1 2 2 2 2 2
H&E: hematoxylin and eosin
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stained for CK5/6 were represented by 3 cores (Fig. 1); the
5 remaining cases by 2 cores. The immunohistochemical
scores of the TMA and the donor blocks are shown in
Table 4. Overall agreement in CK5/6 scores between the
TMA and the donor blocks was 98% with a kappa of 0.93.
For CK14, two cases were excluded because only one
tumor core was left and three cases were also excluded
because the two available cores had discrepant immunohis-
tochemical scores. Fifty (85%) of 59 cases had complete
agreement (Table 4). Four cases were scored one class
higher on TMA when compared with the full sections.
Conversely, five other cases were classified lower on TMA
with one case two classes lower. Kappa score was 0.71.
Regarding E-cadherin staining, three assessable cores
were present in 89% of the cases; two cores in 11%. Overall
agreement in E-cadherin staining scores was accomplished
in 72% of cases (Table 5). In one case, a higher score was
found on the TMA compared to the full section. In 17
cases, the expression of E-cadherin was scored lower on
TMA than on the full sections. The observed kappa was
0.47.
Three-core analysis of Ki-67 staining could be per-
formed in 78% of selected cases and two-core analysis in
19%. Two cases were represented by a single tumor core
and were, therefore, excluded from further analysis. Ki-67
staining was scored as “moderate” on both TMA and full
sections in 42 (69%) of 61 selected cases. In 79% of cases,
the Ki-67 scores of the TMA were similar to that of the full
sections. Thirteen cases were discordant (Table 6); kappa
was 0.42.
With regard to p53 staining, two cores were present in
12 (19%) cases and 3 cores were available in 51 (80%)
cases. One case was excluded as it was represented by only
one TMA core. Complete agreement was achieved in 87%
of the selected tumors (Table 6). In the eight nonconcordant
cases, the difference was one class, resulting in a kappa of
0.86.
Discussion
After its introduction in 1998, TMA technology has been
applied in the immunohistochemical analysis of various
malignancies, including squamous cell carcinomas and
adenocarcinomas of the esophagus [3, 5, 18, 19, 25, 41].
Although it seems a very attractive method for high-
throughput analysis of hundreds of tissues simultaneously,
it may have limitations as the evaluation of the marker
Table 3 Agreement in the degree of differentiation between TMA
cores and full sections
Full section
G1 G2 G3 Total κ
TMA G1 2 3 0 5
G2 2 21 2 25
G3 0 7 26 33
Total 4 31 28 63 0.65
G1: well-differentiated, G2: moderately differentiated, G3: poorly
differentiated
Fig. 1 Example of strong CK5/
6 staining in TMA cores and the
corresponding full section. a
Three TMA cores representing
one tumor; magnification ×20. b
Enlargement of the middle TMA
core depicted in a; magnifica-
tion ×100. c Part of the slide of
the donor block of the same
tumor; magnification ×100
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tissue cores of only 0.6 mm in diameter, especially for
proteins that are heterogeneously expressed or that are cell
cycle-dependent [36]. It is, therefore, essential to assess in
each type of cancer individually and for every molecular
marker whether TMA technology is feasible and valid [8,
33]. To our knowledge, this has not been done in
esophageal cancer.
In our TMA containing triplicate cores of 108 ESCCs, a
median of 9% of cores was uninformative (6% lost during
tissue processing and 3% containing too little tumor),
which is comparable to the results reported in other studies
[7, 8, 27]. Improper selection of representative tumor areas
on the donor block’s H&E slide by the pathologist or
incorrect punching of these representative areas out of the
donor block can cause tissue cores that contain too little
tumor. Possible causes of absent cores are the size and
fragility of the tumor tissue used and the aggressiveness of
tissue processing applied [31, 35, 42].
Moreover, the number of available cores on the TMA
slide depends on the level at which the TMA paraffin block
has been sectioned. The slides stained for H&E, CK14,
Ki-67, and p53 were one of the first slides that were cut
from our TMA block, whereas sections stained for CK5/6
and E-cadherin were taken slightly deeper. On these latter
sections, a lower number of absent cores was observed
(Table 2), showing that not all cores were placed at the
exact same level in the TMA block during TMA construc-
tion, mainly due to dissimilar thicknesses of the donor
paraffin blocks that were used to construct the TMA [34].
The agreement in immunohistochemical results of the
markers between our TMA and the full sections varied from
moderate to almost perfect (κ=0.42 to 0.93), which is
consistent with the results reported in other TMAvalidation
studies [4, 7, 8, 31, 35]. The observed variation in
agreement could be due to tumor heterogeneity, topograph-
ical variation in the expression pattern of the molecular
marker, or to the scoring criteria used [31].
Regarding tumor heterogeneity, the optimal amount of
tissue cores incorporated in the TMA has been a matter of
debate. Several validation studies have shown that three
cores are highly representative for the full section [6, 11,
12, 28]. The addition of a fourth core did not add to the
percentage of agreement in a colorectal cancer TMA [12].
Moreover, the more cores punched per case, the fewer cases
can be placed into the TMA reducing throughput. Adding a
fourth core may nevertheless be worthwhile in tissues prone
to uninformative cores due to small lesions such as
dysplasias or carcinomas in situ [42]. In our TMA, the
amount of uninformative cores was low (5–10%), probably
because ESCCs have a large diameter, thereby increasing
the chance of obtaining a core containing tumor tissue.
Taken together, we consider it justified to utilize three
biopsy cores in ESCCs. Nonetheless, using such a low
amount of cores requires careful selection of the tumor
regions by an experienced pathologist to deal with the
heterogeneity of the tumor in the TMA [33].
The agreement between TMA and full sections was
substantial to almost perfect for CK5/6 and CK14. Because
91% of cases have shown a very strong expression of CK5/
Table 6 Agreement in immunohistochemical scores between TMA
cores and full slides stained for Ki-67 and p53
Full sections
<10% 10–50% ≥50% Total κ
TMAs Ki-67
<10% 2 1 0 3
10–50% 3 42 3 48
≥50% 0 6 4 10
Total 5 49 7 61 0.42
p53
<10% 19 3 0 22
10–50% 0 1 2 3
≥50% 0 3 35 38
Total 19 7 37 63 0.86
Table 5 Agreement in immunohistochemical scores between TMA
cores and full slides stained for E-cadherin
Full sections
E-cadherin <50% ≥50% Total κ
TMA <50% 22 17 39
≥50% 1 24 25
Total 23 41 64 0.47
Table 4 Agreement in immunohistochemical scores between TMA
cores and full slides stained for CK5/6 and CK14
Full sections
<10% 10–80% ≥80% Total κ
TMAs CK5/6
<10% 1 1 0 2
10–80% 0 4 0 4
≥80% 0 0 58 58
Total 1 5 58 64 0.93
CK14
<10% 5 2 1 8
10–80% 0 11 2 13
≥80% 0 4 34 38
Total 5 17 37 59 0.71
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molecular marker does not subdivide ESCCs and conse-
quently will not be a prognostic marker for this malignancy.
CK14 was more evenly distributed over the three scoring
groups, but because one case was scored two classes lower
on TMA when compared to the full section, kappa was
lower when compared to CK5/6.
The relatively moderate concordance in case of Ki-67
may be explained by the fact that almost 80% of cases were
situated in one category (staining of 10–50% of tumor cells)
with 13 discordant cases deviating from this category. E-
cadherin also had a moderate concordance, mainly because
the relatively faint staining intensity of this molecular
maker made its assessment in our TMA very difficult
(Fig. 2).
TMA technology was also found to be valid for
determining the histologic grade of differentiation in ESCC.
Complete agreement between TMA and full sections
occurred in 78% (49 out of 63; κ=0.65) of selected cases,
which is high when compared to the 40% agreement
achieved in a TMA of bladder cancer [22]. Due to its
homogeneous staining pattern, p53 showed excellent
concordance (κ=0.86) in our microarray (Fig. 3).
The concurrence between the TMA and the full sections
is affected by the cut-off values of the immunohistochem-
ical scoring system of the stainings as well [7, 31]. The
Fig. 2 Representative example
of E-cadherin staining in TMA
cores and the corresponding full
section. a Three TMA cores
representing one tumor; magni-
fication ×20. b Enlargement of
the right TMA core depicted in
a; magnification ×100. c Part of
the slide of the donor block of
the same tumor;
magnification ×100
Fig. 3 Representative example
of p53 staining in TMA cores
and the corresponding full sec-
tion. a Three TMA cores repre-
senting one tumor;
magnification ×20. b Enlarge-
ment of the left TMA core
depicted in a; magnification
×100. c Part of the slide of the
donor block of the same tumor;
magnification ×100
512 Virchows Arch (2008) 452:507–514application of a two-class scoring system in an endometrial
cancer TMA improved κ to 1.0 compared to 0.81 with a
three-class system [7]. In our study, the two-class scoring
systemdidnotsubstantiallyaffectthekappa(datanotshown).
Because the E-cadherin expression had a verylow intensity in
our ESCCs, we have chosen to apply a two-class system. In
addition, the cut-off values indicating a strong immunohisto-
chemicalexpressionwereset higherinthe cytokeratins(80%)
than in the other molecular markers (cut-off value 50%)
because otherwise practically all tumors would be designated
having a strong expression of cytokeratins.
Now that our esophageal cancer TMA has been
validated, it will be used to correlate the expression of
various molecular pathways with clinicopathologic data,
aiming at detecting markers of prognostic significance and
molecular targets for new therapies. Because the agreement
between TMA slides and full sections depended on the
molecular marker stained for, it should be considered to
assess the expression pattern of a marker on a full section
first, before staining a TMA slide. When a focal or
heterogeneous expression pattern is noticed, it might be
more valuable to assess marker expression by means of full
sections instead of TMA. On the other hand, when a marker
shows a homogeneously diffuse expression pattern, staining
a TMA slide does allow for high-throughput screening of
tumors. When a prognostic molecular marker has been
identified by means of TMA technology, it is recommended
to verify the results by full-section analysis.
In conclusion, this study has demonstrated TMA
technology to be a valid method for immunohistochemical
analysis in ESCC with agreement levels for well-known
molecular markers with different staining potential between
TMA and full sections ranging from moderate to almost
perfect.
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